President Donald Trump announced on Monday January 20 that the United States will leave the World Health Organization (WHO).

The post Trump announces US withdrawal from WHO appeared first on NLS.

CSL Behring Denmark has announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec).

The post First Danish patients treated with gene therapy for haemophilia B appeared first on NLS.

First approval in the US for AstraZeneca and Daiichi Sankyo’s Datroway based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy.

The post AstraZeneca’s Datroway approved in the US appeared first on NLS.

The European High Performance Computing Joint Undertaking (EuroHPC) has selected seven proposals to establish and operate the first AI Factories across Europe, and two of them are located in the Nordic region. 

The post Kajaani and Linköping to host European AI factories appeared first on NLS.

Vedran Beglerbegovic is appointed as the new CEO of SyntheticMR.

The post SyntheticMR appoints new CEO appeared first on NLS.

Orexo has announced that rights to future transaction proceeds and royalty on future net revenues for the drug candidate vipoglanstat (OX-MPI), have been converted to shares in Gesynta Pharma.

The post Orexo converts future rights for OX-MPI to shares in Gesynta appeared first on NLS.

Gesynta Pharma has secured SEK 304 million in a Series B financing round led by Innovestor Life Science.

The post Gesynta Pharma raises SEK 304 million appeared first on NLS.

NordForsk has decided to fund three Nordic networking activities to support knowledge development on the post-COVID condition (PCC).

The post New Nordic consortia on post-COVID condition appeared first on NLS.

A new international study led by researchers at Karolinska Institutet shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.

The post New research shows that AI can improve ovarian cancer diagnoses appeared first on NLS.

IDRx is a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.

The post GSK to acquire IDRx for up to USD 1.15 billion appeared first on NLS.